Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 53Carcinoma, Hepatocellular 43Breast Neoplasms 33Small Cell Lung Carcinoma 29Squamous Cell Carcinoma of Head and Neck 23Cholangiocarcinoma 22Urinary Bladder Neoplasms 21Colorectal Neoplasms 21Pancreatic Neoplasms 20Ovarian Neoplasms 17Triple Negative Breast Neoplasms 16Biliary Tract Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 12Neoplasms 11Carcinoma, Renal Cell 11Liver Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Uterine Cervical Neoplasms 7Esophageal Neoplasms 7Carcinoma, Squamous Cell 7Adenocarcinoma Of Esophagus 7Recurrence 6Prostatic Neoplasms 6Mesothelioma, Malignant 6Melanoma 6Gallbladder Neoplasms 6Fallopian Tube Neoplasms 6

Interventions

Cisplatin 17Radiotherapy 11Cetuximab 11Surveys and Questionnaires 10pembrolizumab 9Biopsy 9Radiation 8Magnetic Resonance Spectroscopy 8Drug Therapy 8Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Carboplatin 7X-Rays 6Specimen Handling 6Fluorouracil 6Celecoxib 6Standard of Care 5Paclitaxel 5Observation 5Sentinel Lymph Node Biopsy 4Interviews as Topic 4Chemoradiotherapy 41,2-diaminocyclohexaneplatinum II citrate 4Watchful Waiting 3Ultrasonography 3Taxes 3Practice Guidelines as Topic 3Positron Emission Tomography Computed Tomography 3Platinum 3Optical Imaging 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Mouth Neoplasms × durvalumab × Clear all
NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
39 enrolled 8 charts
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
18 enrolled 10 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡